Kevin Trinh, MD
Interventional Pain Medicine · Dublin, CANPI 1962724153
Payments from drug & device makers
Across 54 payments — averaging $64.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- SPR Therapeutics, Inc$709
- Boston Scientific$332
- Abbott$279
- Globus Medical$238
- Stryker$122
- plus $251 from 7 others
What the payments were for
- Consulting fees$40512%
- Travel & lodging$81724%
- Food & beverage$2,25065%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 16 | $1,540 |
| SPR Therapeutics, Inc | 4 | $709 |
| Boston Scientific | 13 | $332 |
| Abbott | 6 | $279 |
| Globus Medical | 3 | $238 |
| Stryker | 1 | $122 |
| Nevro Corp. | 3 | $76 |
| Kuros Biosciences USA, Inc | 2 | $52 |
| GRT US Holding, Inc. | 2 | $48 |
| Biotronik NRO, Inc. | 1 | $21 |
| Avanos Medical | 1 | $20 |
| Stimwave Technologies Incorporated | 1 | $19 |
| Medline Industries LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$971
- SPRINT PNS System$665
- Accurian$137
- ETERNA$128
- mild Device Kit$122
- INCEPTIV$103
- Senza$101
How this compares
$3,472 in reported general payments places this provider in the 50th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 217 | $3,853 |
| Pregabalin | 58 | $1,760 |
| Baclofen | 39 | $595 |
| Diclofenac Sodium | 22 | $568 |
| Celecoxib | 18 | $406 |
| Nabumetone | 11 | $132 |
| Eszopiclone | 11 | $114 |
| Prednisone | 23 | $46 |
| Meloxicam | 17 | $41 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Dublin
- Sheldon JordanSanta Monica$3.1M
- Ezekiel FinkBeverly Hills$2.3M
- Matthew DotyOroville$1.3M
- Tim LeierRancho Mirage$749K
- Pragya GuptaEscondido$647K
- Michael Verdolinla Mesa$563K
- Standiford HelmOrange$476K
- Patrick BuchananCamarillo$453K
- Roy BrownlowSan Diego$452K
- Andrew GermanovichRancho Mirage$408K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.